COLL
NASDAQ
US
Collegium Pharmaceutical, Inc. - Common Stock
$32,31
▼ $-0,94
(-2,83%)
Vol. 584K
11
Punteggio di Qualità
ok
Analisi approfondita
2/5
ok
Ricavi ✓
Utile netto ✓
>IPO ✗
Cap. mercato
$1.5B
P/E
25,0
ROE
24,1%
Margine
7,7%
D/E
294,07
Beta
0,65
52W
$23–$50
Consenso Wall Street
12 analisti · Apr 20263
Acquisto forte
7
Compra
2
Mantieni
0
Vendi
0
Vendita forte
83,3%
Rating Compra
Grafico dei Prezzi
Titoli simili
Utili
Tasso di battuta: 75,0%
Prossimo report
Mag 06, 2026
Stima EPS: $1,64
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $1,64 | — | — |
| Dic 2025 | $2,37 | $2,04 | $-0,33 |
| Set 2025 | $2,08 | $2,25 | +$0,17 |
| Giu 2025 | $1,65 | $1,68 | +$0,03 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $181.9M | $177.8M | $188.0M | $209.4M | $205.4M |
| Utile netto | — | $12.5M | $2.4M | $12.0M | $31.5M | $17.0M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 15.6% | 15.6% | 15.6% | 15.6% | 24.1% | 24.1% |
| P/E (TTM) | 26.20 | 32.67 | 30.74 | 31.27 | 25.08 | 25.04 |
| Net Margin | 6.4% | 5.1% | 5.1% | 5.1% | 7.7% | 7.7% |
| Gross Margin | 57.6% | 56.7% | 56.7% | 56.7% | 57.2% | 57.2% |
| D/E Ratio | 354.39 | 354.39 | 354.39 | 354.39 | 294.07 | 294.07 |
| Current Ratio | 1.18 | 1.18 | 1.18 | 1.18 | 1.36 | 1.36 |
Rapporti chiave
ROA (TTM)
3,6%
P/S (TTM)
1,93
P/B
4,0
EPS (TTM)
$1,49
CF/Share
$4,22
Crescita ricavi 3A
+31,6%
52W High
$50,01
52W Low
$23,23
$23,23
Intervallo 52 settimane
$50,01
Salute finanziaria
Flusso di cassa libero
$122.4M
Debito netto
$583.6M
Liquidità
$231.3M
Debito totale
$814.9M
Aggiornato al Dic 31, 2025
Як COLL виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Micro-cap Pharmaceuticals (All) · 171 компаній
Оцінка COLL vs аналоги Pharmaceuticals
P/E
25,0
▲
12%
sopra
peer
(22,4)
vs Peer
vs Settore
Sottovalutato
P/S
1,9
▼
61%
sotto
peer
(5,0)
vs Peer
vs Settore
Sottovalutato
P/B
4,0
▲
90%
sopra
peer
(2,1)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(2,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість COLL vs аналоги Pharmaceuticals
ROE
24,1%
▲
144%
sopra
peer
(-54,3%)
vs Peer
vs Settore
Top livello
Net margin
7,7%
▲
116%
sopra
peer
(-47,4%)
vs Peer
vs Settore
Sotto media
Валова маржа
57,2%
▼
16%
sotto
peer
(68,3%)
vs Peer
vs Settore
Debole
ROA
3,6%
▲
110%
sopra
peer
(-37,4%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя COLL vs аналоги Pharmaceuticals
D/E ratio
294,1
▲
18995%
sopra
peer
(1,5)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
1,4
▼
60%
sotto
peer
(3,4)
vs Peer
vs Settore
Liquidità bassa
Beta
0,7
▼
31%
sotto
peer
(0,9)
vs Peer
vs Settore
Più volatile
Радар фундаменталів COLL
COLL
Mediana peer
Industria
COLL прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
COLL vs аналоги: ключові метрики
Segnali Correlati
Attività insider
NeutralAcquisti
0
Vendite
0
DIETER DAVID
General Counsel · Mar 18
13976 shs
DIETER DAVID
General Counsel · Mar 09
6224 shs
DREYER SCOTT
Officer · Mar 03
49976 shs
KARNANI VIKRAM
Chief Executive Officer · Feb 10
111795 shs
DREYER SCOTT
Officer · Feb 10
49725 shs
SMITH THOMAS BRAIN M.D.
Officer · Feb 10
37042 shs
TUPPER COLLEEN
Chief Financial Officer · Feb 10
59155 shs
DIETER DAVID
General Counsel · Feb 10
31199 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 38,89%Blackrock Inc.
16,06%
$165.4M
Vanguard Group Inc
7,11%
$73.2M
Eventide Asset Management L…
5,91%
$60.9M
Renaissance Technologies, L…
5,09%
$52.5M
Fuller & Thaler Asset Manag…
4,72%
$48.7M
Aggiornato al Dic 31, 2025